• Merit Medical Systems recently issued fourth-quarter 2025 earnings guidance, projecting revenue between US$389,000,000 and US$395,000,000 year-over-year, and confirmed a Board leadership change with F. Ann Millner appointed Chair following the resignation of longtime director and former Chair Fred P. Lampropoulos.
• This combination of updated revenue expectations and a shift in Board leadership brings fresh attention to how Merit balances growth ambitions with governance continuity.
• Next, we will examine how the new US$389–395 million revenue guidance could influence Merit Medical Systems’ existing investment narrative.

This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.

Merit Medical Systems Investment Narrative Recap

To own Merit Medical Systems, you need to believe its portfolio of interventional and diagnostic products can keep gaining share as procedure volumes rise, while the company manages cost pressures and reimbursement hurdles. The new fourth quarter 2025 revenue guidance of US$389,000,000 to US$395,000,000, alongside the Board transition to F. Ann Millner as Chair, does not materially change the near term focus on securing reimbursement and controlling elevated operating expenses as key catalysts and risks.

The updated fourth quarter revenue outlook is the most directly relevant new data point here, because it feeds into expectations around whether Merit's recent investment in acquisitions, R&D and sales infrastructure is translating into top line growth sufficient to support those higher costs. As investors watch how the new Chair and leadership team oversee this spending, the question is whether growth in cardiovascular and endoscopy product lines can offset tariff, China and reimbursement headwinds without eroding profitability.

Yet behind these encouraging revenue expectations, investors still need to be aware of the risk that...

Merit Medical Systems' narrative projects $1.8 billion revenue and $197.2 million earnings by 2028. This requires 7.0% yearly revenue growth and about a $78 million earnings increase from $119.1 million today.

Uncover how Merit Medical Systems' forecasts yield a $103.55 fair value, a 24% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members currently see fair value for Merit between US$77.42 and US$103.55 across 2 independent views, underscoring how far opinions can diverge. Against that backdrop, the company’s higher operating expenses and dependence on premium priced products such as WRAPSODY CIE highlight why you may want to consider several different growth and risk scenarios before forming your own view.

Explore 2 other fair value estimates on Merit Medical Systems - why the stock might be worth 7% less than the current price!

Build Your Own Merit Medical Systems Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Merit Medical Systems research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Merit Medical Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Merit Medical Systems' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• These 18 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.